Analysts think EDSA stock price could increase by 331%
Aug 09, 2025, 11:25 AM
17.37%
What does EDSA do
Edesa Biotech, headquartered in Markham, Ontario, focuses on developing clinical-stage drugs for inflammatory diseases, including EB05 for ARDS and EB01 for chronic allergic dermatitis. The company employs 16 staff and went public in 2008.
5 analysts think EDSA stock price will increase by 330.99%. The current median analyst target is $9.18 compared to a current stock price of $2.13. The lowest analysts target is $5.05 and the highest analyst target is $17.85.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
